Journal
BLOOD REVIEWS
Volume 24, Issue 1, Pages 1-9Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2009.11.002
Keywords
Leukaemia; Myeloid; Chronic; Stem cells; Drug resistance; Protein kinase inhibitors
Categories
Funding
- Bristol-Myers Squibb
Ask authors/readers for more resources
The introduction of imatinib, a tyrosine kinase inhibitor (TKI) that targets the BCR-ABL protein, has revolutionised the treatment of chronic myeloid leukaemia (CML), producing high rates of response that have been durable in many patients. However, because of intrinsic or acquired mechanisms of imatinib resistance, in addition to the persistence of leukaemic stem cells that are resistant to imatinib-induced apoptosis, imatinib treatment does not appear to be curative. Cytogenetic and molecular monitoring enable the identification of patients showing signs of treatment failure and can be used to guide choices regarding subsequent therapeutic options, including imatinib dose escalation, treatment with a secondary TKI or, in selected cases, allogeneic stem cell transplant (allo-SCT). Although these alternative therapies may overcome imatinib resistance, long-term remission or cure from CIVIL is likely to require development of novel interventions that effectively eliminate CML stem cells (Ph+HSC). (c) 2009 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available